U.S. market Closed. Opens in 11 hours 32 minutes

ANTX | AN2 Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
RevenueN/AN/AN/AN/AN/A
Cost of RevenueN/A77.00KN/AN/AN/A
Gross ProfitN/A-77.00KN/AN/AN/A
Operating Expenses69.64M42.26M21.57M7.28M5.18M
Selling, General & Admin14.76M12.75M4.67M1.26M289.00K
Research & Development54.87M29.51M16.91M6.02M4.89M
Other Operating ExpensesN/A-45.00K-38.00K-6.32MN/A
Operating Income-69.64M-42.26M-21.57M-7.28M-5.18M
Other Expenses / Income4.90M1.31M31.00K-6.32M-457.00K
Before Tax Income-64.73M-40.96M-21.54M-13.60M-5.63M
Income Tax Expenses-69.64K514.00K-69.00K-3.00K-31.07K
Net Income-64.73M-41.47M-21.47M-13.60M-5.63M
Interest ExpensesN/A514.00KN/AN/AN/A
Basic Shares Outstanding23.60M19.40M18.74M18.74M18.74M
Diluted Shares Outstanding23.60M19.40M18.74M18.74M18.74M
EBITDA-69.64M-42.26M-21.57M-7.28M-5.18M
EBITDA Margin0.00%0.00%0.00%0.00%0.00%
EBIT-64.80M-40.44M-21.54M-13.60M-5.67M
EBIT Margin0.00%0.00%0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙